Comparison of Intravenous Injection of Calcium Antagonist and Beta-blockade on Endothelial Shear Stress of Coronary Artery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01171911|
Recruitment Status : Unknown
Verified April 2010 by Nanjing Medical University.
Recruitment status was: Not yet recruiting
First Posted : July 29, 2010
Last Update Posted : July 29, 2010
Both calcium channel antagonist and beta-blocker have cardioprotective effect. Endothelial shear stress is predictive factor of clinical outcomes in patients with obstructive stenosis.
The present study aims at comparing the re-distribution of shear stress and blood velocity during whole cardiac cycle after trans-coronary injection of Nicardipine and esmolol.
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome Coronary Artery Disease||Drug: Nicardipine , Esmolol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Nanjing First Hospital, Nanjing Medical University|
|Study Start Date :||October 2010|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||December 2010|
Drug: Nicardipine , Esmolol
- Endothelial shear stress assessed by computational fluid dynamics [ Time Frame: After four minutes ]At the peak effect of drug that the mean blood pressure (MBP) reduced by 10% or more, or the heart rate increased by 10-15 bpm.
- Minimal lumen area by intravascular ultrasound [ Time Frame: After four minutes ]At the peak effect of drug that the mean blood pressure (MBP) reduced by 10% or more, or the heart rate increased by 10-15 bpm.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01171911
|Contact: Shaoliang Chen, Directoremail@example.com|
|Nanjing First Hospital,Nanjing Medical University||Not yet recruiting|
|Nanjing, Jiangsu, China, 210006|
|Contact: Shao-liang Chen, Director +86-25-52208048 firstname.lastname@example.org|
|Study Chair:||Shao-liang Chen, Director||Nanjing First Hospital, Nanjing Medical University|